⌕
ALPS Cohen & Steers Global Realty Majors ETF · GRI · Nasdaq
Tenet 47 · Mixed
Compare
$1.12−11.81%At closeTenet 47 · Mixed
$1.12−0.15 (−11.81%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD

ALPS Cohen & Steers Global Realty Majors ETF (GRI) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● GlobeNewsWireSep 28, 2026 · 08:40 ET
GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit

Chief Executive Officer Marc Hertz and Chief Scientific Officer Vipin Kumar to present on translating immune biology and clinical signals into novel therapeutic approaches for IPF…

● Zacks Investment ResearchSep 14, 2026 · 13:00 ET
GRI Bio, Inc. (GRI) Upgraded to Buy: What Does It Mean for the Stock?

GRI Bio, Inc. (GRI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).…

● BenzingaSep 14, 2026 · 11:47 ET
UPDATED: Watching GRI Bio; Zacks Investment Research Upgrades Stock To Buy

https://www.zacks.com/stock/news/2989341/gri-bio-inc-gri-upgraded-to-buy-what-does-it-mean-for-the-stock…

● GlobeNewsWireSep 8, 2026 · 08:15 ET
GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars

New whole blood RNA sequencing data identified coordinated, consistent change in genes governing immune re-balancing, myofibroblast inhibition, fibrolysis, basement membrane repair, re-epithelialization, antitussive effe…

● GlobeNewsWireAug 27, 2026 · 09:01 ET
GRI Bio Featured in "Why Now" On-Demand Video Webcast

Video webcast now available  here…

● GlobeNewsWireAug 24, 2026 · 09:05 ET
GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026

LA JOLLA, CA, Aug. 24, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company developing innovative therapies for inflammatory, fibrotic and autoimmune diseases, today …

No recent releases where the company itself is speaking.

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

ANT13−7.0%
AAPL8+0.3%
FOX6−2.9%
META6−2.2%

Article counts from the last market-wide feed page, across every symbol we track and not just GRI · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.